Nasdaq
$0.9327▲ 0.29%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.6MShares out 1.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 10.8After-hours26.10.09 05:076-KKey event#●●●#●●●
XORTX Therapeutics Inc.
XORTX Therapeutics plans to file a Clinical Trial Application (CTA) with Health Canada for its gout therapeutic candidate, XRx-026 (XORLO). This initiative aims to accelerate the collection of clinical data to support a planned New Drug Application (NDA) with the U.S. FDA and expand the company's global regulatory strategy.…more
$0.9327+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.18Pre-market26.09.18 21:056-KKey event
XORTX Therapeutics Inc.
XORTX Therapeutics plans to submit an Investigational New Drug (IND) application to the U.S. FDA for its gout treatment candidate, XRx-026, in the fourth quarter of 2026. This submission aims to advance the company's regulatory pathway toward a New Drug Application (NDA) and target the U.S. gout market, which is estimated at over $700 million annually.…more
$0.9327+0.29%vs prev closeView filingShare - 9.10After-hours26.09.11 05:176-KKey event
XORTX Therapeutics Inc.
XORTX Therapeutics has initiated the clinical and commercial manufacturing of its gout treatment candidate, XORLO. This production process is a foundational step to support the XRX-OXY-102 clinical study and to generate the validation and stability data required for future US FDA marketing approval.…more
$0.9327+0.29%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Overnight26.10.09 15:50#●●●#●●●
XORTX Therapeutics Jumps 22% on Gout Drug Clinical Trial Filing
XORTX Therapeutics shares surged after the company announced plans to file a Clinical Trial Application with Health Canada for its gout drug candidate. The company expects this Canadian study to accelerate its future New Drug Application process with the FDA.…more
$0.9327+0.29%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8After-hours26.10.09 05:00
●●●●●●●● ●●●●● ●●●●●●
XORTX Therapeutics announced its plan to file a Clinical Trial Application with Health Canada for its gout treatment candidate, XRx-026. This move is intended to accelerate the company's clinical data collection to support a future New Drug Application with the U.S. FDA.…more
$0.9327+0.29%vs prev close - 9.18Pre-market26.09.18 21:05
●●●●●●●● ●●●●● ●●●●●●
XORTX Therapeutics announced plans to submit an Investigational New Drug (IND) application to the FDA for its gout treatment, XRx-026, in the fourth quarter of 2026. While the company aims to move toward a New Drug Application (NDA), the timeline remains subject to clinical trial success and sufficient funding.…more
$0.9327+0.29%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report